— 1 — | | 杆解决方案，服务全国多个省级行政区的数字政府建设项目， | | --- | --- | | | 助力安全可靠的数字化中国建设，去年公司在信创领域也有着 | | | 不错的成绩，目前正在服务几个重要项目，公司仍在不断积累 | | | 项目经验，希望打造几个灯塔类项目，为后续信创业务的开展 | | | 拓宽道路。感谢您对公司的关注！ | | | 年亏损，今年采取了什么补救措施？ 2、公司已经连续 3 | | | 答：尊敬的投资者您好！公司围绕开源，聚焦主业和创新 | | | 业务，持续推动研发和技术创新，通过与行业头部厂商的合作 | | | 在信创领域布局新赛道，培育第二增长曲线。另外，公司已从 | | | 多方面开展降本增效工作，在成本控制方面，通过全链条成本 | | | 结构优化及供应链协同降本；在费用管理方面，严格预算管理， | | | 合理安排资金，控制各项费用支出，提高精细化管理水平。未 | | | 来公司将以财务战略驱动资源高效配置，提升盈利能力和股东 | | | 回报水平。感谢您对公司的关注！ | | | 3、正元大厦什么进展？ | | | 答：尊敬的投资者您好！正元大厦位于国家 ...

Market Performance - The three major indices experienced fluctuations, with the Shanghai Composite Index down 0.18%, Shenzhen Component down 0.61%, and ChiNext down 0.68% as of the close on May 27. The total trading volume in the two markets was approximately 998.9 billion yuan [2]. Sector Performance - The glyphosate and agricultural chemical sectors saw significant gains, with Zhongqi Co., Ltd. (300575.SZ) rising by 20%, Yabenn Chemical (300261.SZ) up over 12%, and other companies like Hailir Chemical (603639.SH) and Lier Chemical (002258.SZ) increasing by 10% [2]. - The consumer goods and food & beverage sectors also performed well, with Jin Feng Wine Industry (600616.SH), Junyao Health (605388.SH), and Kuaiji Mountain (601579.SH) all rising by 10% [3]. - The medical and CRO concept stocks strengthened, with Sanofi (688336.SH) increasing by over 15% and Junshi Biosciences (688180.SH) rising by 7.69% [3]. Policy Impact - Following the issuance of the "Special Action Plan to Boost Consumption" by the Central Committee and the State Council, various regions have introduced their own plans to stimulate consumption, such as Hebei Province's goal of a 5% growth in retail sales by 2025 and Hainan's commitment of over 10 billion yuan to support consumption from 2025 to 2027 [3]. Industry Outlook - CITIC Securities reported that the pharmaceutical sector is expected to show the best market returns in the first half of 2025, driven by policy optimization, commercial health insurance, and AI industry catalysts. The report suggests that the second half of 2025 will see a more certain performance and valuation recovery in the healthcare industry [4]. - The real estate sector also showed positive performance, with companies like Bright Real Estate (600708.SH) rising over 9%. Analysts noted that the easing of real estate policies and supportive fiscal measures are expected to further stimulate demand [5].

Investment Rating - The report maintains an investment rating of "Recommended" for the machinery equipment industry [2][51]. Core Views - The machinery industry is experiencing structural opportunities driven by policy support, technological iteration, and globalization, despite recent market underperformance [4][51]. - April excavator sales increased by 17.6% year-on-year, indicating a recovery in both domestic and export markets, supported by new replacement cycles and favorable policies [52][53]. - The manufacturing PMI recorded at 49, reflecting a slight decline, but the report suggests potential structural opportunities amidst a weak recovery [53][54]. Summary by Sections Industry Performance - The machinery equipment index fell by 2.22% from May 19 to May 23, ranking 30th among 31 primary industries, with all sub-industries showing declines [4][51]. - Notable declines were observed in automation equipment (-3.42%) and general equipment (-3.45%) [4][51]. Excavator Sales - In April 2025, a total of 22,142 excavators were sold, marking a 17.6% increase year-on-year, with domestic sales at 12,547 units (up 16.4%) and exports at 9,595 units (up 19.3%) [52][53]. - From January to April 2025, total excavator sales reached 83,514 units, a 21.4% increase year-on-year, with domestic sales up 31.9% and exports up 9.02% [52][53]. Manufacturing PMI - The manufacturing PMI for April 2025 was recorded at 49, down 1.4 percentage points year-on-year and 1.5 percentage points month-on-month [53][54]. - New orders PMI was at 49.2, and production PMI at 49.8, indicating a contraction in manufacturing activity [53][54]. Industrial Robot Production - In April 2025, industrial robot production surged by 51.5% year-on-year, totaling 71,547 units, attributed to government policies promoting equipment upgrades [54][54]. - The report suggests potential investment opportunities in high-tech segments such as reducers and servo systems, as well as system integrators benefiting from diverse application scenarios [54]. Key Companies to Watch - The report highlights several companies for potential investment, including XCMG Machinery (000425.SZ), Sany Heavy Industry (600031.SH), and Zoomlion Heavy Industry (000157.SZ) in the excavator segment [52][53]. - For the machine tool sector, companies like Huazhong CNC (300161.SZ) and Neway CNC (688697.SH) are recommended due to expected demand growth from government support [53][54].

Group 1 - The Shanghai Composite Index turned positive on May 27, with the Biopharmaceutical ETF (159859) rising by 0.28% at the time of reporting [1] - Notable gainers within the Biopharmaceutical ETF included Dizhe Pharmaceutical-U, which increased by over 3%, along with Teva Biopharmaceuticals, Kailaiying, and Wantai Biological Pharmacy [1] - The Innovative Drug ETF Tianhong (517380) saw a decline of 0.33%, with Zhejiang Pharmaceutical rising by over 3%, while Ruizhi Pharmaceutical dropped by 3% [1] Group 2 - On May 26, the Biopharmaceutical ETF (159859) experienced a net inflow of 35.36 million yuan despite a drop of 0.57%, while the Innovative Drug ETF Tianhong (517380) had a net inflow of 3.6 million yuan despite a decline of 1.64% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ), which includes the top 30 securities in the biopharmaceutical sector based on market capitalization and liquidity [1] - The Innovative Drug ETF Tianhong, launched in 2021, has a scale of 389 million yuan as of May 26, and is the only product covering the entire market for the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [2] Group 3 - Minsheng Securities remains optimistic about the pharmaceutical sector, particularly in the innovative drug and new consumption areas, highlighting ongoing catalysts in the innovative drug sector [2] - Key focus areas for the innovative drug sector include anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy directions, along with an emphasis on domestic production and medical consumption, especially in the beauty sector [2]

Group 1 - The Hang Seng Index and Hang Seng Tech Index experienced fluctuations, with the Hang Seng Healthcare Index rising by 2.88% and the Hang Seng Healthcare Index ETF (159557) increasing by 2.82% with a turnover rate exceeding 3% [1] - Notable stocks in the healthcare sector included Federated Pharmaceutical, which rose over 8%, along with other companies like CSPC Pharmaceutical and Kangzheng Pharmaceutical also showing gains [1] - The upcoming American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3, 2025, is expected to showcase over 70 research results from Chinese pharmaceutical companies, highlighting innovative drug candidates with potential for best-in-class status [1] Group 2 - Citic Securities indicated a clear trend of performance and valuation recovery in the healthcare industry, with a focus on innovation-driven strategies and internationalization, as well as reforms in outpatient marketing models for the second half of the year [2] - The A-share pharmaceutical sector and Hong Kong's innovative drug sector are currently at five-year low positions, with public fund holdings in the pharmaceutical industry reaching their lowest point since Q2 2020 in Q4 2024, but showing signs of recovery in Q1 2025 [2] - The global pharmaceutical investment and financing scale has shifted from a downward trend to a low-level oscillation upwards, with many growth-oriented pharmaceutical companies currently having PEG levels below 1, indicating potential for performance and valuation improvements [2] Group 3 - China’s innovative drug licensing out (Lisence out) total amount is projected to exceed $50 billion in 2024, reaching $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total in similar transactions [3] - The record licensing amount for SSGJ-707 is expected to accelerate the trend of Chinese pharmaceutical companies expanding internationally, with a noticeable increase in the number and value of licensing out agreements in recent years [3]

Group 1 - The issuance of equity funds is experiencing a surge, with nearly 80 equity funds currently or soon to be launched, indicating a potential influx of new capital into the market [1] - Among the newly issued equity funds, 52 are currently in the issuance process, while 27 are set to be launched soon, showcasing a diverse range of investment options including broad-based and thematic index funds [1] - The new floating management fee funds have gained significant attention, with 26 funds approved and 16 set to launch on May 27, marking a shift in the industry focus from "scale" to "returns" [1][2] Group 2 - Several high-performing fund managers are leading the new floating management fee funds, with a mix of growth and value investment styles, aligning performance benchmarks with their investment strategies [2] - Many of the new floating management fee funds have set fundraising caps between 2 billion to 8 billion, suggesting a competitive issuance environment [2] - Fund companies are emphasizing the importance of fund retention rates and sustainable management post-issuance, indicating a strategic focus on long-term investment ecosystems [3] Group 3 - Fund managers are optimistic about equity assets, identifying numerous structural opportunities, particularly in the context of AI-driven technological innovation and evolving consumer demands [4] - The current economic resilience and ongoing policy support contribute to a positive long-term market outlook, as expressed by fund managers [5]

Summary of Conference Call for Aisen Co., Ltd. Industry Overview - The focus for investment this year (2025) is on self-sufficiency, particularly in the equipment and materials sectors, with domestic companies actively replacing foreign products [2][3] - The advanced packaging sector is trending towards higher integration and heterogeneous integration, with 2.5D and 3D packaging becoming key directions for GPU and AI chip development [2][4] Company Insights - Aisen Co., Ltd. has launched mass production of its positive DNQ series photoresist products, with a high market share expectation, while the negative acrylic series holds about a low double-digit percentage [2][6] - The company is conducting chemical amplification RDL photoresist tests, with client validation expected in the second half of the year, aiming for a comprehensive product layout [2][6] - Aisen's positive DNQ and negative acrylic series have gained market share in the domestic advanced packaging sector, which primarily uses JSR's post-film revival photoresist [2][7] Market Dynamics - The HBM memory market is currently dominated by international giants, but domestic companies are gradually entering this space [2][7] - Due to international political factors, the supply of HPV3 and subsequent products is limited, necessitating independent development of related technologies in China [2][8] - The TSV (Through-Silicon Via) technology is crucial in HBM structures, and Aisen is developing TSV photoresist and high-speed copper plating products [2][9] Product Development and Strategy - Aisen is focusing on developing new PSPI materials to meet the diverse needs of advanced packaging, with plans to become a leading supplier in this area within two to three years [2][4][14] - The company has established a strategic partnership with Shenghe Jingwei, focusing on electroplating and photoresist products, with significant sales growth expected [2][26] - Aisen's business performance in the advanced packaging sector is projected to grow rapidly, with a target of achieving significant sales in the wafer and advanced packaging fields [2][14][31] Challenges and Opportunities - The ongoing trade tariff war has increased material procurement costs for several packaging and testing companies, prompting a shift towards domestic materials [2][33] - The domestic PSPI market is still in its infancy, with a market size of approximately 1.5 billion RMB, and Aisen is working to increase its market share through product development and client validation [2][17][22] - The company is addressing supply chain challenges by developing multiple alternative solutions to mitigate reliance on single products [2][19] Future Outlook - Aisen anticipates structural growth driven by increasing demand from domestic clients, particularly in the HBM sector, and plans to expand its product offerings to meet market needs [2][28] - The company aims to enhance its domestic replacement rate and market share through improved risk control and technology advancements [2][25]

Group 1 - The core point of the news is the significant asset restructuring plan between Zhongke Shuguang and Haiguang Information, where Haiguang plans to absorb and merge with Zhongke through a share exchange, aiming to strengthen its main business in the information technology industry [1][3]. - Haiguang Information is the only high-end processor manufacturer based on x86 architecture in China, focusing on CPUs and DCUs, while Zhongke Shuguang specializes in high-end computers, storage, security, and data center products [3]. - As of March 2025, Zhongke Shuguang holds 650 million shares of Haiguang Information, representing a 27.96% stake, making it the largest shareholder of Haiguang [3]. Group 2 - The merger is expected to create a larger entity that can achieve valuation premiums, similar to Pfizer's acquisition of Wyeth, which increased its market valuation significantly [4]. - The strategic merger is anticipated to reshape the industry landscape by enhancing technological collaboration, accelerating the iteration of domestic CPUs and GPUs, and improving the capabilities of key industry solutions [4]. - The new entity will compete with major players like Huawei and Inspur, while also addressing potential monopoly risks and enhancing supply chain security [4].

Core Viewpoint - The military industry sector is experiencing significant investment interest, particularly in military ETFs, driven by global geopolitical conflicts and advancements in China's military trade capabilities [1][2]. Group 1: Investment Trends - Military ETF (512660) has seen a net inflow of over 750 million yuan in the past five days, with a current scale of nearly 14 billion yuan, marking a nearly 40% increase in shares this year, making it the largest in its category [1]. - The military ETF closely tracks the CSI Military Index, which includes companies in aerospace, military electronics, shipbuilding, and weaponry, reflecting the overall performance of the military industry [2]. Group 2: Military Trade Developments - China's military trade products are gaining global attention due to their comparative advantages and improved production capabilities, with a focus on performance, cost-effectiveness, and production capacity [2]. - Pakistan, a key military trade partner, has sourced 81.15% of its military imports from China over the past five years, showcasing the high performance and cost-effectiveness of Chinese military equipment during recent conflicts [2]. Group 3: Industry Outlook - The military sector is expected to see strong domestic demand growth driven by the "14th Five-Year Plan," "Centenary of the Army," and "self-reliant domestic substitution" strategies, indicating a positive industry outlook [2].

证券研究报告·行业跟踪周报·燃气Ⅱ 燃气Ⅱ行业跟踪周报 库存大幅增长美国气价回落，需求偏弱国内 气价回落，库存偏低欧洲气价微增 增持（维持） [Table_Tag] [投资要点 Table_Summary] ◼ 风险提示：经济增速不及预期、极端天气、国际局势变化、安全经营风险。 2025 年 05 月 26 日 证券分析师 袁理 执业证书：S0600511080001 021-60199782 yuanl@dwzq.com.cn 证券分析师 谷玥 执业证书：S0600524090002 guy@dwzq.com.cn 行业走势 -13% -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 燃气Ⅱ 沪深300 相关研究 《需求偏弱美国&国内气价回落，库 存同比偏低欧洲气价微增；对美 LNG 关税降至 25%》 2025-05-19 《产量或下降美国气价提升，库存同 比偏低欧洲气价提升》 2025-05-12 东吴证券研究所 1 / 13 请务必阅读正文之后的免责声明部分 ◼ 价格跟踪：库存大幅增长美国气价回落 ...